Patterns of recurrence in triple negative breast cancer patients (automated IHC) : An Indian Tertiary Care Center data.

Ghosh, Joydeep; Agarwal, Sanjit; Ganguly, Sandip; Dabkara, Deepak; Biswas, Bivas; Nandi, Shibarati; Chakraborty, Santam; Datta, Soumitra Shankar; Ahmed, Rosina; Chatterjee, Sanjoy

doi:10.1200/jco.2018.36.15_suppl.e13128

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To more accurately understand the differences in patient outcome in TNBC, we sought to understand distinct clinical and genomic features among primary TNBCs categorized based on outcome: rapid (rrTNBC), late (lrTNBC) and no relapse (nrTNBC). In several large TNBC cohort studies, the median time to distant metastasis was around 2 years, ranging from 19.7 to 31.2 months, [ 2 , 14 – 16 ] thus we define rrTNBC as relapse or death within 24 months of diagnosis. We previously demonstrated in two large cohorts (Surveillance, Epidemiology, and End Results Program/SEER and National Comprehehensive Cancer Network/NCCN) that disparities in sociodemographic features are strongly associated with rrTNBC, including insurance type, race, and surgical management [ 17 – 19 ].…”

Section: Introductionmentioning

confidence: 99%

Genomic features of rapid versus late relapse in triple negative breast cancer

et al. 2021

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features of primary tumors. Methods Using three publicly-available datasets, we identified 453 patients diagnosed with primary TNBC with adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; distant relapse or death ≤2 years of diagnosis), ‘late relapse’ (lrTNBC; > 2 years) or ‘no relapse’ (nrTNBC: > 5 years no relapse/death). We explored basic clinical and primary tumor multi-omic data, including whole transcriptome (n = 453), and whole genome copy number and mutation data for 171 cancer-related genes (n = 317). Association of rapid relapse with clinical and genomic features were assessed using Pearson chi-squared tests, t-tests, ANOVA, and Fisher exact tests. We evaluated logistic regression models of clinical features with subtype versus two models that integrated significant genomic features. Results Relative to nrTNBC, both rrTNBC and lrTNBC had significantly lower immune signatures and immune signatures were highly correlated to anti-tumor CD8 T-cell, M1 macrophage, and gamma-delta T-cell CIBERSORT inferred immune subsets. Intriguingly, lrTNBCs were enriched for luminal signatures. There was no difference in tumor mutation burden or percent genome altered across groups. Logistic regression mModels that incorporate genomic features significantly outperformed standard clinical/subtype models in training (n = 63 patients), testing (n = 63) and independent validation (n = 34) cohorts, although performance of all models were overall modest. Conclusions We identify clinical and genomic features associated with rapid relapse TNBC for further study of this aggressive TNBC subset.

show abstract

Section: Introductionmentioning

confidence: 99%

Genomic features of rapid versus late relapse in triple negative breast cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Median time to relapse in the total cohort was 19.7 months, which is similar to that of large published cohorts. 3,6,11,12 Overall, 16.9% (n5509) of included patients with TNBC had rrTNBC. These patients were more likely to be younger and non-White, have less education and lower income, have Medicare or Medicaid/indigent insurance, and have a higher disease stage at diagnosis compared with those who did not have rrTNBC (supplemental eTable 2).…”

Section: Resultsmentioning

confidence: 99%

“…rrTNBC was defined as distant metastatic recurrence or death from any cause #24 months after diagnosis based on large TNBC cohort studies. 3,6,11,12 We included only patients with $24 months follow-up or those who had a survival event within that time frame, and excluded those with de novo metastatic disease. We also excluded patients who did not receive chemotherapy within 9 months of diagnosis, and included those who received either neoadjuvant or adjuvant chemotherapy.…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study

Asad

Barcenas

Bleicher

et al. 2021

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) accounts for disproportionately poor outcomes in breast cancer, driven by a subset of rapid-relapse TNBC (rrTNBC) with marked chemoresistance, rapid metastatic spread, and poor survival. Our objective was to evaluate clinicopathologic and sociodemographic features associated with rrTNBC. Methods: We included patients diagnosed with stage I–III TNBC in 1996 through 2012 who received chemotherapy at 1 of 10 academic cancer centers. rrTNBC was defined as a distant metastatic recurrence event or death ≤24 months after diagnosis. Features associated with rrTNBC were included in a multivariable logistic model upon which backward elimination was performed with a P<.10 criterion, with a final multivariable model applied to training (70%) and independent validation (30%) cohorts. Results: Among all patients with breast cancer treated at these centers, 3,016 fit the inclusion criteria. Training cohort (n=2,112) bivariable analyses identified disease stage, insurance type, age, body mass index, race, and income as being associated with rrTNBC (P<.10). In the final multivariable model, rrTNBC was significantly associated with higher disease stage (adjusted odds ratio for stage III vs I, 16.0; 95% CI, 9.8–26.2; P<.0001), Medicaid/indigent insurance, lower income (by 2000 US Census tract), and younger age at diagnosis. Model performance was consistent between the training and validation cohorts. In sensitivity analyses, insurance type, low income, and young age were associated with rrTNBC among patients with stage I/II but not stage III disease. When comparing rrTNBC versus late relapse (>24 months), we found that insurance type and young age remained significant. Conclusions: Timing of relapse in TNBC is associated with stage of disease and distinct sociodemographic features, including insurance type, income, and age at diagnosis.

show abstract

“…[1,2,14] To more accurately understand the differences in patient outcome in TNBC, we sought to understand distinct clinical and genomic features among primary TNBCs categorized based on outcome: rapid (rrTNBC), late (lrTNBC) and no relapse (nrTNBC). In several large TNBC cohort studies, the median time to distant metastasis was around 2 years, ranging from 19.7 to 31.2 months, [2,[14][15][16] thus we de ne rrTNBC as relapse or death within 24 months of diagnosis. We previously demonstrated in two large cohorts (Surveillance, Epidemiology, and End Results Program/SEER and National Comprehehensive Cancer Network/NCCN) that disparities in sociodemographic features are strongly associated with rrTNBC, including insurance type, race, and surgical management.…”

Section: Introductionmentioning

confidence: 99%

Genomic Features of Rapid Versus Late Relapse in Triple Negative Breast Cancer 

Zhang

Asad

Weber

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct clinical and genomic features of primary tumors.Methods: Using three publicly-available datasets, we identified 453 patients diagnosed with primary TNBC with adequate follow-up to be characterized as ‘rapid relapse’ (rrTNBC; relapse/death ≤2 years of diagnosis), ‘late relapse’ (lrTNBC; >2 years) or ‘no relapse’ (nrTNBC: >5 years no relapse/death). We explored basic clinical and primary tumor multi-omic data, including whole transcriptome (n=453), and whole genome copy number and mutation data for 171 cancer-related genes (n=317). Association of rapid relapse with clinical and genomic features were assessed using Pearson chi-squared tests, t-tests, ANOVA, and Fisher exact tests. We evaluated logistic regression models of clinical features with subtype versus two models that integrated significant genomic features.Results: Relative to nrTNBC, both rrTNBC and lrTNBC had significantly lower immune signatures and immune signatures were highly correlated to anti-tumor CD8 T-cell, M1 macrophage, and gamma-delta T-cell CIBERSORT inferred immune subsets. Intriguingly, lrTNBCs were enriched for luminal signatures. There was no difference in tumor mutation burden or percent genome altered across groups. Logistic regression mModels that incorporate genomic features significantly outperformed standard clinical/subtype models in training (n=63 patients), testing (n=63) and independent validation (n=34) cohorts, although performance of all models were overall modest. Conclusions: We identify clinical and genomic features associated with rapid relapse TNBC for further study of this aggressive TNBC subset.

show abstract

Patterns of recurrence in triple negative breast cancer patients (automated IHC) : An Indian Tertiary Care Center data.

Cited by 8 publications

References 0 publications

Genomic features of rapid versus late relapse in triple negative breast cancer

Genomic features of rapid versus late relapse in triple negative breast cancer

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study

Genomic Features of Rapid Versus Late Relapse in Triple Negative Breast Cancer

Contact Info

Product

Resources

About

Patterns of recurrence in triple negative breast cancer patients (automated IHC) : An Indian Tertiary Care Center data.

Cited by 8 publications

References 0 publications

Genomic features of rapid versus late relapse in triple negative breast cancer

Genomic features of rapid versus late relapse in triple negative breast cancer

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study

Genomic Features of Rapid Versus Late Relapse in Triple Negative Breast Cancer&nbsp;

Contact Info

Product

Resources

About

Genomic Features of Rapid Versus Late Relapse in Triple Negative Breast Cancer